在直肠癌光子和质子治疗后估计二次癌症风险:计算幻影研究
Nipon Saiwong1, Sasikarn Chamchod2, Pattarakan Suwanbut3
1Princess Srisavangavadhana Faculty of Medicine, Chulabhorn Royal Academy, Bangkok, Thailand.
概括
强度调节的质子疗法 (IMPT) 对直肠癌患者的二次癌症风险低于强度调节的辐射疗法 (IMRT). 一个双边斜 IMPT 计划显示了最低的风险,特别是结肠癌.
科学领域:
- 辐射瘤学
- 医学物理
- 计算生物学
背景情况:
- 结直肠癌的治疗通常涉及放射治疗, 携带二次癌症的风险.
- 强度调节辐射疗法 (IMRT) 和强度调节质子疗法 (IMPT) 是具有不同剂量分布的先进技术.
- 评估二次恶性瘤等长期风险对于优化癌症治疗策略至关重要.
研究的目的:
- 通过计算模型对直肠癌的IMRT和IMPT进行二次癌症风险比较.
- 评估不同的IMPT场配置在最小化辐射诱导风险方面的有效性.
- 为各种治疗计划量化器官特异性终身风险 (LAR).
主要方法:
- 使用计算机模拟泰国直肠癌患者的男性幻影.
- 使用6 MV FFF光子束的Ethos处理计划系统 (TPS) 来生成IMRT计划.
- 使用matRad计算IMPT计划,并使用TOPAS蒙特卡洛二次辐射模拟进行验证.
- 通过器官等效剂量 (OED) 和LAR计算的机制建模来评估二次癌症风险.
主要成果:
- 与IMRT相比,IMPT计划导致风险器官的辐射剂量显著降低.
- 在IMRT和IMPT计划中,结肠表现为二次癌症的LAR最高.
- 与IMRT相比,IMPT计划显示结肠,肠道和膀的LAR减少,而双场斜面IMPT计划是最有利的.
结论:
- 在评估的治疗方式中,双场斜体IMPT计划显示了最低的二次癌症风险.
- 与IMRT相比,IMPT在降低直肠癌患者中辐射诱导的二次癌症风险方面具有潜在的优势.
- 需要进一步的研究和临床验证,以证实这些患者群体的发现.
相关概念视频
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
174
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
174
01:21Cancer Survival Analysis
453
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
453